Magazine-How delays derailed Covid-19 vaccination in Africa
In this issue, we examine how delays derailed Covid-19 vaccination campaigns in Africa, China’s rapid progress in developing CAR-T therapies, how the bear market is affecting…
By
Manasi Vaidya
Manasi Vaidya is the lead editor for Pharmaceutical Technology where she covers the healthcare space. She writes features that look at the research, regulation and reimbursement of drugs with a focus on topics at the intersection of business and science. She is based in Brooklyn and an alum of New York University’s Science, Health and Environmental Reporting program.
Latest articles
All Articles
How to clear your medicine cabinet in an environment-friendly way
While the task of disposing drugs in an eco-safe manner stumps many, drug take-back initiatives look to fill in…
By
Humira retains its frontrunner status as drug spending in US increases by 7.7%
The use of Covid-19 drugs and the continued dominance of specialty drugs contributed to the rise in drug expenditures…
By
Russia sanctions: what next for Sputnik Covid-19 vaccine production around the world?
The Russian invasion of Ukraine has knock-on effects on the Covid-19 pandemic as supplies of Sputnik V vaccine to…
By
Magazine: Cutting the carbon footprint of pharma’s supply chain
In this issue: We examine the supply chain for delivering Covid-19 antivirals, and the pharma industry's quest to decarbonise.
By
Covid-19 antiviral access: uneven supply patterns hinder US rollout
An analysis of the demand for Covid-19 therapeutics allocation has shown that supply dynamics evolve slower than infection rates.
By
Magazine: Mapping the RNA therapeutics R&D landscape in 2022
In this issue: Mapping research trends with RNA therapeutics and artificial intelligence in drug development for 2022, following the…
Trial diversity-it’s time to quit talking and start doing
In order to improve diversity in trials, inequities due to economic factors and race need to be bridged at…
By
iOnctura targets the tumor stroma interface to win over immunotherapy resistance
The Swiss firm is advancing its cancer therapies in the clinic while it gears up to raise funds
By